electroCore (ECOR) Stock Price, News & Analysis

Company Overview

electroCore, Inc. (NASDAQ: ECOR) is a commercial-stage medical device company focused on bioelectronic medicine and non-invasive vagus nerve stimulation (nVNS). Its technology is designed to stimulate the vagus nerve through the neck without requiring surgery or implanted components.

The company’s primary prescription product is gammaCore, a handheld nVNS device used for the acute treatment of pain associated with migraine and episodic cluster headaches in adults. electroCore also markets consumer-oriented products, including Truvaga, a handheld vagus nerve stimulation device positioned for general wellness applications. The company’s products are distributed through healthcare channels as well as direct-to-consumer and commercial partners.

Founded in 2005, electroCore is headquartered in New Jersey and serves customers in the United States and selected international markets. The company has pursued regulatory clearances and commercial distribution for its nVNS technology in multiple geographies. Dan Goldberger serves as electroCore’s chief executive officer.

Key Stats

• Today's Range: $4.92 to $7.92
• 50-Day Range: $7.05 to $12.29
• 52-Week Range: $4.41 to $12.70
• Volume: 455,867 shs
• Average Volume: 91,524 shs
• Market Capitalization: $53.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Hold

electroCore Stock Analysis - MarketRank™

electroCore scored higher than 54% of companies evaluated by MarketBeat, and ranked 481st out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

electroCore has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

electroCore has a consensus price target of $18.00, representing about 211.7% upside from its current price of $5.78.

Amount of Analyst Coverage

electroCore has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for electroCore are expected to grow in the coming year, from ($1.17) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of electroCore is -4.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of electroCore is -4.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.22% of the float of electroCore has been sold short.

Short Interest Ratio / Days to Cover

electroCore has a short interest ratio ("days to cover") of 5.23.

Change versus previous month

Short interest in electroCore has recently increased by 3.30%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

electroCore does not currently pay a dividend.

Dividend Growth

electroCore does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.72

News Sentiment

electroCore has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for electroCore this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added electroCore to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, electroCore insiders have sold 103.48% more of their company's stock than they have bought. Specifically, they have bought $98,350.00 in company stock and sold $200,120.00 in company stock.

Percentage Held by Insiders

7.80% of the stock of electroCore is held by insiders.

Percentage Held by Institutions

26.74% of the stock of electroCore is held by institutions.

Company Calendar

• Last Earnings: 11/04/2026
• Today: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ECOR
• CIK: 1560258
• Web: www.electrocore.com
• Phone: (973) 290-0097
• Fax: N/A
• Employees: 83
• Year Founded: 2005

Price Target and Rating

• Average Price Target for electroCore: $18.00
• High Price Target: $18.00
• Low Price Target: $18.00
• Potential Upside/Downside: +244.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.97 million
• Net Margins: -33.46%
• Pretax Margin: -34.50%
• Return on Equity: N/A
• Return on Assets: -74.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.34
• Quick Ratio: 0.97

Sales & Book Value

• Annual Sales: $32.03 million
• Price / Sales: 1.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.27) per share
• Price / Book: -19.33

Miscellaneous

• Outstanding Shares: 9,230,000
• Free Float: 8,506,000
• Market Cap: $48.18 million
• Optionable: Not Optionable
• Beta: 1.23